Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data | Current Obesity Reports US$ 28.24 Min. order: 1 piece ★★★★★ 4.6 (165 reviews) Sold : Login>>
Upcoming wave of hormone-based therapies set to change field of diabetes, obesity care US$ 28.50 Min. order: 1 piece ★★★★★ 4.2 (60 reviews) Sold : Login>>
Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research US$ 22.23 Min. order: 1 piece ★★★★★ 4.5 (88 reviews) Sold : Login>>
Sermorelin vs CJC-1295/Ipamorelin: Why Modern Medical Clinics Have Moved to the Stack US$ 21.60 Min. order: 1 piece ★★★★★ 4.2 (170 reviews) Sold : Login>>
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has well-established weight-loss benefits. Cagrilintide, a long-acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit US$ 20.79 Min. order: 1 piece ★★★★★ 4.1 (221 reviews) Sold : Login>>
Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare US$ 22.31 Min. order: 1 piece ★★★★★ 4.5 (159 reviews) Sold : Login>>